Members
Margin of Safety Dashboard
Finch Trades
Research Notes
My Profile
Logout
Why Join?
Member Benefits
Stocks We Cover
Public
Articles
Data Visualizations
Newsletter
Newsletter
About
What Is Solt DB?
Public Benefit
Our Lonely Team
Pricing
Login
Newsletter
My Profile
Login
Finch Trades: Bought Codexis (March 2, 2026)
March 4, 2026
By
Maxx Chatsko
11
minute read
Bottom-Up Insights
Finch Trades are
first disclosed on Discord
before a research note is published.
Recent Research
.Finch Trades
Margin of Safety Dashboard
Finch Trades
Research Notes
Finch Trades: Bought Codexis (March 2, 2026)
March 4, 2026
I expect to build a small position in the industrial enzyme specialist this month, but this position will be higher-risk than a precommercial drug developer.
BY
Maxx Chatsko
Finch Trades: Sold Harmony Biosciences (February 26, 2026)
March 4, 2026
My model assumed the threat from generic competition wouldn't arrive until 2030, but a negative surprise from the patent litigation case creates too much uncertainty.
BY
Maxx Chatsko
Finch Trades: Bought Harmony Biosciences (February 20, 2026)
February 20, 2026
I haven't found a reason for shares to lose over 20% of their value in a few days, but the business is healthy and Wakix has considerable commercial momentum. Full-year 2025 earnings are scheduled for next week, so I'll soon learn if there are any negative surprises or if this Opportunistic investment pays off.
BY
Maxx Chatsko
Finch Trades: Sold Arrowhead Pharmaceuticals (December 3, 2025)
December 4, 2025
It pains me to fully exit my position in Arrowhead Pharma, but this transaction can extend my runway to find a real job into the spring.
BY
Maxx Chatsko
Finch Trades: Sold AVITA Medical (May 9, 2025)
May 9, 2025
Things might get worse before they get better. I'd rather not hold through the uncertainty of needing capital in a capital-challenged environment.
BY
Maxx Chatsko
Finch Trades: Bought Harmony Biosciences (May 2, 2025)
May 3, 2025
This is the final short-term investment for Q1 2025 earnings season. As with the others, I'm targeting a return of at least 10%. What characteristics have I looked for?
BY
Maxx Chatsko
Finch Trades: Sold Exact Sciences (May 2, 2025)
May 2, 2025
As previously communicated, I made a series of short-term investments during Q1 2025 earnings season.
BY
Maxx Chatsko
Finch Trades: Sold Blueprint Medicines (May 1, 2025)
May 2, 2025
As previously communicated, I made a series of short-term investments during Q1 2025 earnings season.
BY
Maxx Chatsko
Finch Trades: Bought Blueprint Medicines (April 30, 2025)
May 2, 2025
This is one of multiple short-term investments I expect to make during Q1 2025 earnings season.
BY
Maxx Chatsko
Finch Trades: Bought Exact Sciences (April 30, 2025)
May 2, 2025
This is one of multiple short-term investments I expect to make during Q1 2025 earnings season.
BY
Maxx Chatsko
Finch Trades: Bought Coherus BioSciences (March 27, 2025)
April 1, 2025
The business certainly isn't worth less than $100 million, especially now with the debt overhang removed or in light of the Checkpoint Tx acquisition.
BY
Maxx Chatsko
Finch Trades: Bought Coherus BioSciences (January 21, 2025)
January 22, 2025
I threw some new money at Coherus ahead of the publication of its abstract for ASCO GI, which promised full data from the casdozo triplet in first-line advanced liver cancer.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (January 10, 2025)
January 13, 2025
I previously communicated my intention to deploy my entire Roth IRA contribution to Relay Therapeutics in early 2025. I may have gotten too cute waiting for a better entry point ahead of the JPMorgan Healthcare Conference, but I took advantage of the volatility from Eli Lilly's acquisition of STX-478 to atone my sins.
BY
Maxx Chatsko
Finch Trades: Bought AVITA Medical (January 8, 2025)
January 13, 2025
Management cannot seem to understand the importance of underestimating and overdelivering. I'm interested in a long-term position, so buying at favorable valuations is attractive.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (December 10, 2024)
December 10, 2024
This is my core long-term position. I'm eager to add more shares ahead of the upcoming safety data readout for the RLY-2608 triplet combination with a CDK inhibitor in late 2024 and lower my cost basis.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (December 3, 2024)
December 3, 2024
This is my core long-term position. I'm eager to add more shares ahead of the upcoming safety data readout for the RLY-2608 triplet combination with a CDK inhibitor in late 2024 and lower my cost basis.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (November 20, 2024)
November 21, 2024
This is my core long-term position. I'm eager to add more shares ahead of the upcoming safety data readout for the RLY-2608 triplet combination with a CDK inhibitor in late 2024 and lower my cost basis.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (October 29, 2024)
October 29, 2024
This is my core long-term position. I'm eager to add more shares ahead of the upcoming safety data readout for the RLY-2608 triplet combination with a CDK inhibitor in late 2024 and lower my cost basis.
BY
Maxx Chatsko
Finch Trades: Bought Arrowhead Pharmaceuticals (October 1, 2024)
October 1, 2024
The business is poised for an inflection point in 2024 as it ramps multiple new products and returns to cash-flow positive operations, which has been the primary driver of Wall Street's disinterest in the stock.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (September 25, 2024)
September 25, 2024
This is my core long-term position. I'm eager to add more shares ahead of upcoming data readouts in late 2024 and lower my cost basis.
BY
Maxx Chatsko
Finch Trades: Bought Arrowhead Pharmaceuticals (September 25, 2024)
September 25, 2024
Sentiment for biotech is historically low right now. Although investors are rightfully eyeing Arrowhead Pharmaceuticals' high cash burn with unease, I think the recent punishment is short-sighted.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (September 13, 2024)
September 13, 2024
This is my core long-term position. I'm eager to add more shares ahead of upcoming data readouts in late 2024 and lower my cost basis. Here I specifically played the weekend data readout from Scorpion Therapeutics and STX-478.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (September 5, 2024)
September 5, 2024
This is my core long-term position. I'm eager to add more shares ahead of upcoming data readouts in late 2024 and lower my cost basis.
BY
Maxx Chatsko
Finch Trades: Bought Coherus BioSciences (July 2, 2024)
July 7, 2024
The stock's slide is frustrating, but I think my patience will be rewarded with a respectable exit in late 2024. Cash flow and profitability metrics should improve rapidly as Loqtorzi and Udenyca Onbody ramp.
BY
Maxx Chatsko
Finch Trades: Bought Exact Sciences (May 29, 2024)
July 4, 2024
The business has positive operating cash flow. It could begin generating operating income in 2025 or 2026, depending on how aggressive management wants to be – and if its internal analytics are correct.
BY
Maxx Chatsko
Finch Trades: Bought Relay Therapeutics (May 29, 2024)
July 4, 2024
If I could only buy one stock in the next few years, then it might be Relay Therapeutics. The upcoming data readouts in the second half of 2024 won't represent an inflection point for the stock price, but should reflect a busier pace of announcements going forward.
BY
Maxx Chatsko
Finch Trades: Bought Coherus BioSciences (April 25, 2024)
April 26, 2024
The business is poised for an inflection point in 2024 as it ramps multiple new products and returns to cash-flow positive operations, the deterioration of which has been the primary driver of Wall Street's disinterest in the stock.
BY
Maxx Chatsko